跳至主要内容
临床试验/KCT0004555
KCT0004555招募中未知

Comparison of salvage hypofractionated accelerated versus salvage radiotherapy for biochemical recurrence after radical prostatectomy (SHARE trial): a prospective, randomized controlled, open-label, multi-center, superiority study

Asan Medical Center0 个研究点目标入组 288 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
288

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
o Limit 至 o Limit(—)
性别
Male

入选标准

  • Patients with histologically diagnosed prostate cancer
  • - Prostate cancer of medium risk groups or higher according to the National Comprehensive Cancer Network (NCCN) guidelines
  • - Adults over 20.
  • - Biochemical recurrence after surgery (Definitions: PSA >0.2 ng/mL, =1.0 ng/mL)
  • - Full body performance ECOG 0-1
  • - Finding suitable haematological examination within 6 months prior to research registration
  • Absolute neutrophil count (ANC) = 1500 cells/mm3
  • Platelets = 50,000 cells/mm3
  • Hemoglobin = 8.0 g/dl
  • - Adequate kidney function within 6 months of study registration
  • Creatine < 2.0 ng/dL
  • - Appropriate liver function within 6 months of research registration
  • total bilirubin < 1.5 X normal maximum
  • alignin aminotransferase or aspartate aminotransferase < 2.5 X normal maximum
  • - preSRT PSA = 1 ng/m

排除标准

  • - Imaging examination of surgical site or clinically identified recurrent findings
  • - If pelvic lymph node transfer is confirmed
  • - If teleconversion is confirmed
  • - In case anti-cancer treatment is performed prior to surgery
  • - Past history of exposure to pelvic radiation
  • - Crucial force that has been treated for prostate cancer in cold treatment and near-field radiation
  • - If treated with cancer other than skin cancer and thyroid cancer, NED f/u can be registered after treatment of existing cancer for more than 5 years
  • - In case of severe shared disease

研究者

相似试验